Home News Releases ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US.
ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US.
2013/03/29
